SuperworthQuidelOrtho QDEL
- Market cap
- $941.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.4×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $2.7B
- −2% on a year ago
- Net margin
- −39.2%
- Free cash flow yield
- −22.4%
QuidelOrtho trades at 0.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $2.7B over the last twelve months, down 2% on a year earlier with a −39% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $744M−5% | $742.6M−14% | $711M−16% | $637M−4% | $727.1M−2% | $707.8M−5% | $692.8M−3% | $613.9M−4% | $699.9M−4% | $723.6M+2% | $619.8M−11% | $630.9M+3% | |
| Cost of revenue | $374.6M−1% | $360M−14% | $378.9M−5% | $361M−2% | $374.8M+0% | $381.7M+6% | $349.5M−8% | $339M−6% | $364.3M−3% | $403.2M+6% | $356M+2% | $358M+6% |
| Gross profit | $369.4M−9% | $382.6M−15% | $332.1M−26% | $276M−7% | $352.3M−5% | $326.1M−15% | $343.3M+3% | $274.9M−0% | $335.6M−5% | $320.4M−2% | $263.8M−23% | $272.9M−1% |
| R&D | $61.5M−6% | $59.3M−8% | $59.2M−5% | $56.3M−10% | $55.9M−9% | $47.3M−20% | $53.2M−10% | $45.7M−19% | $41.5M−26% | $45.8M−3% | $44.9M−16% | $48.7M+7% |
| SG&A | $194.1M−5% | $187.6M−12% | $204.7M+1% | $188.2M+5% | $186.4M−4% | $187.5M−0% | $187M−9% | $178M−5% | $186.9M+0% | $194.4M+4% | $199.3M+7% | $189.7M+7% |
| $26.3M−54% | $40.1M−54% | −$1.8B | −$117.5M+337% | $15M−43% | −$100.4M | $32.6M | −$180.7M+54% | −$704.8M | −$66.3M−34% | −$31.8M | −$21.8M−88% | |
| Interest expense | $37.7M+27% | $36.7M+6% | $39M+6% | $41M+12% | $42.9M+14% | $40.6M+11% | $40M+3% | $40.5M−1% | $46.1M+8% | $51M+26% | $51.1M+28% | $54.7M+35% |
| Pre-tax income | −$15.5M | −$9.2M | −$1.8B | −$162.9M+153% | −$28.8M+86% | −$140.9M+1432% | −$8.8M−100% | −$229.6M+41% | −$756.9M+2528% | −$112.4M−20% | −$79.5M+803% | −$81.2M−65% |
| −$2.8M | −$16.2M | −$92.9M | −$15.2M+36% | −$8.9M+218% | $37.5M | $3.9M | $25.8M | −$23.9M+169% | $18.3M−51% | $12.3M+215% | $11.7M−55% | |
| Net income | −$12.7M | $7M−77% | −$1.7B | −$147.7M+178% | −$19.9M+57% | −$178.4M | −$12.7M−99% | −$255.4M+73% | −$733M+3583% | −$130.7M−27% | −$91.8M+623% | −$92.9M−64% |
| −$0.19 | $0.10−78% | −$25.50 | −$2.20+175% | −$0.30+58% | −$2.64 | −$0.19−99% | −$3.77+71% | −$10.78+3493% | −$1.92−27% | −$1.35+611% | −$1.36−64% | |
| 66.9M−1% | 66.8M−0% | 66.9M−0% | 67.1M+0% | 67.3M+1% | 67.5M+1% | 67.5M+1% | 67.7M+1% | 68M+1% | 68.1M+1% | 68.2M+1% | 68.3M+1% |
Revenue: Q1 FY21 and Q1 FY22: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY21 and Q1 FY22: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY21 and Q1 FY22: 6 months less the 3 months printed beside them. 20 periods, Q2 FY21 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY21 and Q1 FY22: 6 months less the 3 months printed beside them.
SG&A: Q1 FY21 and Q1 FY22: 6 months less the 3 months printed beside them.
Operating income: Q1 FY21 and Q1 FY22: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY21 and Q1 FY22: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY21 and Q1 FY22: 6 months less the 3 months printed beside them.
Income tax: Q1 FY21 and Q1 FY22: 6 months less the 3 months printed beside them.
Net income: Q1 FY21 and Q1 FY22: 6 months less the 3 months printed beside them.
EPS, diluted: 6 periods, Q1 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY21: share-days: the 6-month average less the second quarter's. 3 periods, Q4 FY21 to Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest QuidelOrtho's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| QDELQuidelOrtho | $941.5M | n/m | 103× | 0.4× | −2% | −39.2% | |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| CDNACareDx | $3.6B | 33.4× | 19.1× | 7.8× | +34% | 24.2% | |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | 6.9× | +17% | 20.4% | |
| BLLNBillionToOne | $5.1B | 166× | 151× | 12.8× | +90% | 9.5% | |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | 4.2× | +2% | 17.7% | |
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | 9.1× | +85% | 10.6% | |
| Peer median | $4.5B | 60.4× | 50.9× | 7.3× | +26% | 14.2% |
More on QuidelOrtho
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .